AdvaMedDx Announces 2012-2013 Board of Directors

AdvaMedDx, a division of the Advanced Medical Technology Association (AdvaMed) focused on the opportunities and challenges facing companies that discover, develop and manufacture medical diagnostic technologies, has announced its 2012-2013 board of directors.

“I look forward to working closely with the board to drive the mission of AdvaMedDx, which is to partner with stakeholders from across the health care community to improve public health through the appropriate use of innovative diagnostic technologies for early detection and prevention of disease,” said Vincent Forlenza, AdvaMedDx board chairman.

“Membership in AdvaMedDx has doubled, and it is the leading voice of diagnostic manufacturers,” added Stephen J. Ubl, AdvaMed president and CEO. “I’m delighted with the talented and experienced group of leaders that has been assembled to oversee our diagnostics division, and I believe their efforts will make the vision of personalized medicine a reality.”

The members of the board are:

* Edward Michael, executive vice president, diagnostics at Abbott Laboratories;
* Bernhard Sixt, president and CEO at Agendia;
* Ron Zwanziger, president and CEO at Alere Inc.;
* Jonathan Achenbaum, senior vice president, global strategic marketing, diabetes care at Bayer HealthCare (a subsidiary of Bayer AG);
* Vincent Forlenza, CEO and president at Becton Dickinson and Company;
* Thierry Bernard, senior executive vice president, commercial operations and investor relations at bioMerieux sa;
* Norman Schwartz, president and CEO at Bio-Rad Laboratories Inc.;
* Lisa Ashby, president, category management at Cardinal Health;
* John Bishop, CEO at Cepheid;
* Tom Joyce, executive vice president at Danaher Corporation;
* Carl Hull, president and CEO at Gen-Probe Incorporated;
* Cesar Garcia, president and CEO at IRIS International Inc.;
* Nick Valeriani, company group chairman, worldwide franchise chairman, Ortho Clinical Diagnostics at Johnson & Johnson;
* Carsten Schroeder, president, diagnostics at Novartis Diagnostics, a division of Novartis AG;
* Peer Schatz, CEO at Qiagen;
* Doug Bryant, president and CEO at Quidel Corporation;
* Daniel O’Day, chief operating officer at F. Hoffmann-La Roche Ltd.;
* Jerome H. Casey, chief operations officer at Sekisui Diagnostics, a division of Sekisui Medical Co. Ltd.;
* Michael Reitermann, CEO at Siemens Healthcare Diagnostics; and
* John Kershaw, president and CEO at Sysmex America.

“We are thrilled to announce our board for the upcoming term and welcome a number of new directors,” said Andrew Fish, AdvaMedDx executive director. “Our board members’ keen insights and strategic direction are invaluable as we continue to grow the organization and expand our partnerships with patient advocates and other key stakeholders.”